Cashman Neil 4

What Happened

• Neil Cashman, Chief Scientific Officer and Director of ProMIS Neurosciences (PMN), was granted a derivative award covering 50,000 shares on 2026-05-20. The filing shows $0 cash paid at grant (reported value $0) and lists the transaction as an award/grant (code A). This is an option/derivative grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-22 (timely).
• Reported consideration: $0.00 at grant (derivative security); total reported cash value $0.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote: The shares subject to this option vest ratably over four years, subject to continued service through each vesting date (F1).
• Transaction type: Award/Grant of derivative security (code A).

Context

• This filing reflects an option/award grant for compensation purposes. The award vests over time and does not represent immediately tradable shares until options are vested (and exercised, if applicable). Such grants are common for executive compensation and do not, by themselves, indicate buying or selling sentiment.